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Abstract 
 
               
Children with oppositional defiant disorder (ODD) and a concurrent Axis I diagnosis are often 
prescribed drug therapy for attention deficit hyperactivity disorder (ADHD) to manage disruptive 
behavior. However, ODD symptoms tend to be poorly controlled, raising questions about the 
effectiveness of drug therapy in children with the condition. Safety and long term consequences 
of pharmacological agents for ODD are important factors clinicians must consider before 
initiating treatment. The purpose of this literature review is to examine the pharmacodynamics 
and efficacy of drug therapy used for ODD in school-age children and adolescents. Additionally, 
awareness of poor behavior patterns and recognition of symptoms associated with ODD in 
children among health care providers was explored. A literature review exploring ODD and drug 
therapy for ODD and related behavioral disorders was conducted from various online databases. 
Results from 15 reviewed studies suggest that pharmacologic therapy is typically prescribed for 
ODD symptoms when a comorbid condition such as ADHD, a mood disorder, or an anxiety 
disorder is present.  Drug therapy for ADHD has demonstrated effective behavioral outcomes in 
reducing ODD symptom severity in children and tolerable side effects when used for short-term 
therapy. Studies have demonstrated success and better control of ODD symptoms with a focused 
drug therapy regimen. Overall, the benefits of drug therapy can potentially outweigh the risks of 
adverse effects, and improve the quality of life in children with ODD.  In conclusion, uncovering 
the reasons for poorly controlled ODD in children can be of clinical significance to health care 
providers and can support decision making when considering drug therapy for children with this 
condition.  
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1 
Introduction 
Oppositional defiant disorder (ODD) affects young children through the adolescent age 
and is characterized by aggressive behavior, rebelliousness toward authority, and poor anger 
control. Due to the nature of symptoms, ODD creates poor psychosocial interactions across the 
lifespan including, unhealthy relationships with family members, friends, school teachers, and 
additional authority figures.  
Oppositional defiant disorder is diagnosed using the Diagnostic and Statistical Manual of 
Mental Disorders, 4
th
 ed. (DSM-IV). The diagnosis of ODD in children is conducted by 
observing a pattern of behaviors that must be displayed for at least six months and include at 
least four of the following: often loses temper, often argues with adults, often actively defies or 
refuses to comply with adults’ requests or rules, often deliberately annoys people, often blames 
others for his or her mistakes or misbehaviors, is often touchy or easily annoyed by others, is 
often angry or resentful, and is often spiteful or vindictive (Hamilton & Armando, 2008). 
Furthermore, the behavior must cause significant impairment in social, academic, or 
occupational functioning; must occur independently of other mental disorders; and must not meet 
the criteria for conduct disorder or antisocial personality disorder if the client is over the age of 
18 (Hamilton & Armando, 2008). Diagnosis of ODD can be problematic since health care 
providers must differentiate between typical childhood misbehavior and actual disruptive 
conduct. In addition, ODD is often accompanied by comorbid mental health conditions such as 
attention deficit hyperactivity disorder (ADHD) or mood disorder, which further complicate 
diagnoses.  
The cause of ODD is unknown, however researchers believe there are environmental, 
biologic, and genetic influences that contribute to its etiology. Environmental factors include but 
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are not limited to, parental overreaction to behavior at a young age, lower socioeconomic status, 
and maternal depression (Harvey, Metcalfe, Herbert, & Fanton, 2011). Furthermore, research 
suggests decreased sensitivity to hormones and catecholamine’s such as, cortisol, epinephrine, 
and norepinephrine, occurs with ODD and alters the child’s response to punishment. 
Impairments in the frontal lobe and cingulate cortex may contribute to lack of motivation, 
sensitivity to reward for positive behavior, and impulse and emotional control (Matthys, 
Vanderschuren, & Schutter, 2013). Due to the evidence of chemical and hormonal imbalances, 
drug therapy is utilized as a treatment option to control behavior of children living with ODD. 
Since ODD and ADHD are often comorbid conditions, ADHD agents are commonly prescribed 
to control symptoms of both conditions. However, the effectiveness, safety, and maintenance 
abilities of ADHD agents on ODD symptom severity reduction is still being examined.  
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Problem 
Behavioral therapy is the first line of treatment for ODD including interventions at the 
child and parent levels. Behavioral therapy alone is not always effective when a comorbid 
disorder is present. Therefore, pharmacologic treatment is initiated as an alternative method to 
manage ODD symptoms. A plethora of pharmacologic agents are used for ODD treatment 
including, stimulants (Ritalin, Concerta, Aderall), selective norepinephrine reuptake inhibitors 
(Atomoxetine), mood stabilizers, antidepressants, and antipsychotics (Smith & Coghill, 2010). A 
major problem concerning drug therapy in children with ODD arises due to the lack of research 
and knowledge surrounding safety, efficacy, and long-term success of treatment with ADHD 
drugs on children and adolescent’s ODD symptoms. The pharmacodynamics and 
pharmacokinetics are poorly understood in children as well. The presence of comorbid 
conditions such as ADHD, depression, or anxiety with ODD influences the choice and 
effectiveness of pharmacological agents. ODD can be difficult to diagnose which can lead to 
poor management. Nurses have the opportunity to intervene at the elementary school by raising  
awareness regarding ODD symptoms and increasing knowledge about risk factors that can 
hinder early recognition of the illness.  
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Purpose 
The purpose of this literature review was to explore the effectiveness of ADHD 
pharmacologic agents used to manage ODD. The focus was on whether pharmacologic agents 
used for ODD are safe, effective, and have long-term sustainability of symptom control on 
children and adolescents. Emphasis was placed on the pharmacokinetics and pharmacodynamics 
of prescribed medicines (for ODD) in adolescents. The secondary purpose was to address issues 
with poor control of ODD symptoms. The literature review discussed the role of school nurses 
and existing education gaps. Several subtopics related to poor management of ODD including 
lack of knowledge among parents, frequent comorbid conditions, and broad diagnosis criteria we 
researched as well.  
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Methods 
Research was obtained from EBSCO which collected articles from a variety of databases 
including CINAHL, ERIC, MEDLINE, PsycARTICLES, PsycBOOKS, PsycINFO, and 
Academic Search Premier. To narrow the results, limitations were set to full text, peer reviewed, 
written in the English language, subject age of 6 to 17, publication date from 2000 – 2013, and 
human focused. For CINAHL specifically, an additional inclusion was met for any author that 
was a nurse. ODD and medications were used as inclusion criteria, while demographics and 
behavioral therapy were used as exclusion criteria. The search yielded 638 articles. With the 
addition of the key search terms medication* and children*, 172 studies were remaining. The 
articles were reviewed and chosen based relevance to pharmacologic treatments for ODD and the 
disease process. 30 total articles were utilized in the literature review. For the table of articles, 40 
were eliminated for not being peer reviewed clinical trials or not focusing on one medication. An 
additional four were excluded for not focusing on an ADHD medication specifically, leaving a 
total of six articles for analysis. The six articles selected were all randomized, double-blind, 
placebo-controlled clinical trials. A supplemental search was done in EBSCO involving ODD, 
nursing, and treatment to obtain information about the nurses role in management. Lastly, a 
search was done outside of the EBSCO database to find articles related to the diagnosis of ODD.  
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Background 
Prevalence of ODD and ADHD Comorbidity 
 According to the Diagnostic and Statistical Manual of Mental Disorders (4
th
 ed., text 
rev.; DSM-IV-TR; American Psychiatric Association, 2000) ODD effects about 2 – 16 % of the 
general population. Before puberty ODD is more common in males however after puberty, 
prevalence is equal among sexes. Lastly, about half of the children with ADHD have ODD as 
well (4
th
 ed., text-rev.; DSM-IV-TR; American Psychiatric Association, 2000).  
Brief Description of Scales Used to Measure ADHD and ODD Symptom Severity 
 A variety of scales are used to quantify ADHD and ODD symptoms. From knowledge 
the researcher knows the scales are either parent, teacher, or clinician rated. 
ADHD Rating Scale, Version IV (ADHD-RS-IV)  
 The ADHD-RS-IV (DuPaul, Power, Anastopoulos, & Reid, 1998), based on diagnostic 
criteria from the DSM-IV, is an 18-item scale consisting of two subscales: inattention and 
hyperactivity. There is a parent questionnaire and a teacher questionnaire focusing on symptom 
frequency over six months to assess treatment response in children and adolescents with ADHD 
(Goodman et al., 2010).  
Conners’ Parent Rating Scale – Revised: Short Form (CPRS-R:S) 
 The CPRS-R: S (Conners, 1997) has 27 items and is used to assess ADHD symptoms 
such as inattention, hyperactivity/impulsivity, learning problems, executive functioning, 
aggression, peer relations, and family relations. The scale evaluates oppositonal behavior as well.  
Swanson, Nolan, & Pelham Rating Scale IV (SNAP-IV) 
 The SNAP-IV (Swanson, 1992) evaluates ADHD, ODD, and additional psychiatric 
disorders that occur in childhood. Inattention, hyperactivity/impulsivity, and DSM-IV criteria for 
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ODD are subscale focus areas. The SNAP-IV is used in clinical trials to measure the efficacy of 
ADHD treament (Bussing et al., 2008). 
Clinical Global Impressions Scale (CGI) 
 The CGI scale (Guy, 1976), is used by researchers to measure global functioning of an 
individual before and after medication treatment. There are two components of the scale to 
measure severity (CGI-S) and improvement (CGI-I) (Busner & Targum, 2007). According to 
Busner & Targum (2007) the CGI scale summerizes, “patient history, psychosocial 
circumstances, symptoms, behavior, and the impact of the symptoms on the patient’s ability to 
function”. 
Child Health Questionnaire (CHQ) 
 The CHQ (Landegraf, Abetz, & Ware, 1996) is utilized by researchers to evaluate the 
influence of health issues on a child’s functioning and well-being (Waters, Salmon, & Wake, 
2000). The CHQ is not specific to ADHD or ODD but can be used to assess any illness during 
childhood.  
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Review of Literature 
Atomoxetine Studies 
An eight week, randomized, double-blind, placebo study was conducted on children ages 
8 – 18 with ADHD and with or without comorbid ODD (Newcorn, Spencer, Biederman, Milton, 
& Michelson, 2005). Of 293 subjects, 115 had ODD and 178 did not. Tools to measure the 
effectiveness of atomoxetine on symptom management included, the ADHD-RS-IV-Parent 
verson, CPRS-R: S, CGI-S, and a parent questionnaire. Results showed that atomoxetine was 
more effective than the placebo in decreasing ADHD and ODD symptoms. ADHD children with 
comorbid ODD needed a higher dose of 1.8 mg/kg/day to see results. Children with only ADHD 
showed improvement with only 1.2 mg/kg/day (Newcorn, et al., 2005). Using the CHQ 
Psychosocial Summary scale, quality of life was assessed. Improvements were seen in 
individuals with and without ODD however, subjects with ODD had lower scores at baseline. 
The findings showed that children with ADHD and comorbid ODD exhibit a decrease in 
functioning compared to children with only ADHD. (Newcorn et al., 2005). Adverse effects 
were described to be typical of atomoxetine and significance was not discussed.  
 An eight week, multi-site, randomnized, placebo-controlled trial was done on children 
ages 6 – 15 with ADHD and comorbid ODD. The purpose was to measure the efficacy of 
atomoxetine on 137 children that failed to improve in a six week psychological, parent training 
program (Dell'Agnello et al., 2009). Various rating scales were used by the researchers and 
parents to measure the efficacy of atomoxetine. Results revealed that atomoxetine improved 
ADHD and ODD symptoms, especially inattention, hyperactivity, and oppostional behavior. 
Best results were seen with atomoxetine and concurrent psychotherapy for the parent and child. 
As for safety, 45.8% of children on atomextine complained of nausea, vomiting, and abdominal 
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pain while 43.0% complained of anorexia. Additonal adverse effects with atomextine included 
somnolence (29.9%), headache (21.5%), influenza (8.4%), nervosuness (6.5%), and insomnia 
(4.7%). Only three participants withdrew from the trial because of adverse events (Dell’Agnello, 
et al., 2009). The study results showed atomoxetine was effective and tolerated well.  
 An additional study examined the effectiveness of atomoxetine in controlling ODD and 
ADHD symtoms (Bangs et al., 2008). The researchers conducted an eight week study consisting 
of 131 children, ages 6 – 12, who were randomly chosen to receive 1.2 mg/kg/day of 
atomoxetine or a placebo. Efficacy was measured using the SNAP-IV ODD total scores. There 
was a significant decrease in ODD symptom severity with the atomoxetine treated group at 
weeks two and five, however no noticed improvement at week eight. ADHD symptom severity 
decreased through the entire study. As for safety, atomoxetine was well tolerated. Some adverse 
effects were seen more when compared to the placebo group. For example, atomoxetine subjects 
reported decreased appetites (24.4%), nausea (20.5%), and fatigue (17.3%) as compared to 1.4%, 
8.6%, and 5.7% for the placebo group. Diastolic blood pressures were increased (9.7% increased 
5 mm HG or more above the 95
th
 percentile) and weights decreased (3.5% from baseline) in the 
atomoxetine group (Bangs, et al., 2008).  
Researchers analyzed 98 children from two similar studies involving atomoxetine versus 
a placebo in ADHD children with comorbid ODD (Kaplan et al., 2004). The studies examined 
the efficacy and safety of atomoxetine in children ages 7 – 13. Both studies were double-blind, 
randomized, placebo-controlled trials. Efficacy was measured utilizing the ADHD-RS-IV and 
through interviews with the parents and children. Researchers found automoxetine to be very 
effective in reducing ADHD symptoms, but not ODD symptoms when compared to the placebo 
group. The medication was very well tolerated and only caused minimal adverse effects such as 
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decrease in appetite and emotional lability. Of the 98 participants, one dropped out because of 
hostility and two others withdrew because of nervousness (Kaplan et al., 2004). 
Hazell et al. (2006) conducted a randomized, double-blind, placebo-controlled study to 
examine the influence of comorbid ODD on relapse of symptoms during nine months of 
treatment with atomoxetine for ADHD. The research was a continuation of a 10 week 
atomoxetine trial for subjects that responded well to treatment. Dosages of the 10 week trial 
ranged from 0.5 mg/kg/day to 1.8 mg/kg/day of atomoxetine. To progess in the open-label trial, 
participants had to achieve at least a 25% reduction from baseline data on the ADHD RS total 
score. Consequently, successful participants were ages 6 – 15 and were randomly chosen to 
either continue receiving atomoxetine or switch to a placebo. Of 416, 292 continued with 
atomoxetine and 124 received placebo. 17% of patients with ODD and ADHD relapsed while 
26% of patients with ADHD without ODD relapsed during the study. In the study, atomoxetine 
treatment was effective in preventing relapse of symptoms and even benefited patients that 
relapsed anyway. For example, of all relapsed patients, the ones on atomoxetine benefited longer 
than the ones that received the placebo (Hazell et al., 2006). Although the study did not focus on 
ODD symptoms specifically, results showed that atomoxetine is effective for treatment of 
ADHD with comorbid ODD over a longer period of time. 
Non Peer Reviewed Clinical Trials 
Dittman et al. (2011) completed a nine week, randomized, placebo-controlled, double-
blind on 180 children (ages 6 – 17) diagnosed with ADHD and comorbid ODD. The  purpose 
was to examine the effectiveness of atomoxetine and to compare fast versus slow titration. The 
preferred dose was 1.2 mg/kg/day. Results showed a significant decrease of ADHD and ODD 
symptoms with atomoxetine. In regards to safety, adverse effects such as fatigue, sleep disorders, 
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nausea, and gastrointestinal issues were seen in 60.0% of the fast titrated group and in 44.3% of 
the slow titrated group (Dittman, et al., 2011). Slowly increasing the medication dose was better 
tolerated.To summarize, atomoxetine was effective in reducing ADHD and ODD symptoms and 
relatively safely.  
 Wehmeier et al. (2011) conducted a randomized, placebo-controlled, double-blind, nine 
week study to observe the effects of atomoxetine on quality of life (QOL) in children ages 6-17 
with ADHD and comorbid ODD or conduct disorder (CD). The dose of atomoxetine was started 
low at 0.5 mg/kg and titrated either fast or slow to a target dose of 1.2 mg/kg. Although the main 
focus of the research was QOL, safety and effectiveness was examined weekly for the first three 
weeks and then bi-weekly until the ninth week. Results were measured through the use of the 
SNAP-IV and additional behavioral scales. Reseachers found the use of atomoxetine to be more 
successful at reducing ADHD, ODD, and CD symptoms compared to the placebo. There was no 
significant difference in the fast or slow titrated groups. For safety, more than 10% of 
participants and at least one member in each sub-group (fast titrated, slow titrated, and placebo) 
experienced adverse effects. Fatigue, nausea, headache, vomiting, upper abdominal pain, and 
anorexia were reported the most (Wehmeier et al., 2011). 
 
Clonidine in Combination with a Psychotimulant Study 
 Hazell and Stuart (2003) studied the use of clonidine in combination with a 
psychostimulant to decrease hyperactivity and aggression in children with ADHD combined with 
ODD or CD. The six week, single blind trial consisted of 60 participants ages 6 – 14 that had 
been treated for less than three months with methylphenidate or dexamphetamine. Subjects were 
randomly assigned to receive a 0.10 mg morning and evening dose of clonidine or a placebo. 
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Using the CPRS-R: S to gauge results, the clonidine-treated participants yielded better results 
compared to the placebo group. For example, 57% of the subjects that received clonidine had 
scores decrease more than 38% on the rating scale as compared with a 21% decrease in the 
placebo group. As an added benefit, clonidine helped in decreasing side effects from the 
concurrent psychotropic medications. There were expected adverse effects in the clonidine 
treated group including dizziness and drowsiness but only in the early stages of the trial. The 
results of the study suggest that clonidine works well as an adjunct with a psychostimulant in 
decreasing ADHD and ODD or CD symptoms. 
 
Mixed Amphetamine Salts Extended Release (MAS XR) (Adderall XR) Study 
 Spencer et al. (2006) conducted a four week, multicenter, randomized, double-blind, 
parallel-group, placebo-controlled, forced-dose-escalation study. Before the study began, there 
was a one to four week period where all psychotropic medications were discontinued and a 
placebo was administered. After the discontinuation, there were 308 participants ranging from 
ages 6-17, randomly chosen to receive either 10, 20, 30, or 40 mg/d of MAS XR or a placebo. 
All 308 participants were diagnosed with ODD but only 244 had comorbid ADHD. Efficacy was 
measured using ODD portions of the SNAP-IV parent and teacher rating. Participants and 
parents also attended regular check-up visits in order for researches to collect data regarding 
safety. The data included recording reported adverse effects and observing trends in vital signs, 
12-lead electrocardiograohic (ECG) findings, laboratory results, and physical examinations. 
Results showed the largest decrease in symptoms with the MAS XR 30 and 40 mg/d groups in 
particpants with and without comorbid ADHD. Regarding safety, adverse affects were reported 
more often from the MAS XR including decreased appetite (25.3%), insomnia (19.5%), 
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headache (18.5%), and abdominal pain (10.7%). Weight loss ranged from 1.1 – 3.5 pounds in the 
MAS XR group as compared to no weight loss in the placebo group. 
 
Immediate Release Methylphenidate Study 
 A two week study consisting of 31 children ages 6 – 12 was conducted to observe the 
effectiveness of methylphenidate in controlling ODD symptoms. All participants had ODD, 
ADHD, and either Tourette’s or chronic multiple tic disorder (Gadow, Nolan, Sverd, Sprafkin, & 
Schneider, 2008). Under double-blind conditions, subjects were given placebo and three doses of 
methylphenidate (Novartis Brand Ritalin-IR 0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg) administered 
twice daily. Efficacy was measured by one physician observation and computer vigilance testing 
every two weeks, at a clinic. Parents and teachers completed rating scales two times per week 
throughout the entire study as well (Gadow et al., 2008). Although there were differences 
between parent and teacher ratings, improvement of ODD symptoms were seen with 
methylphenidate as compared to the placebo. In reference to safety, the higher the dosage of 
methylphenidate, the higher the adverse effects. For example, parents rated physical complaints 
higher with the methylphenidate dosages. There was a directly proportional relationship between 
higher methylphenidate dosages and higher heart rates and systolic blood pressures as well 
(Gadow, et al., 2008).  
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Discussion 
Efficacy of ADHD agents 
Ten articles were reviewed and four ADHD medications were observed for efficacy in 
controlling ODD symptoms. The medications included atomoxetine, clonidine, MAS XR 
(Aderrall XR), and methylphenidate. Overall, the four medications were relatively effective in 
reducing ODD symptom severity. 
Of the ten studies reviewed, six dicussed aotomoxetine. The atomoxetine clinical trials, 
with the exception one, showed a greater decrease in ODD symptoms with medication compared 
to a placebo. Bangs et al. (2008) found that overall, atomoxetine reduced ODD symptoms and 
while there was progression throughout the study, there was no significant improvement noted 
over the last three weeks. The effective dosage of atomoxetine varied amongst studies. Dittman 
et al. (2011), Wehmeier et al. (2011), and Bangs et al. (2008) found 1.2 mg/kg/day to be 
effective in decreasing disruptive behaviors. On the other hand, Newcorn et al. (2005) found 1.2 
mg/kg/day of atomoextine sufficient to help ADHD, however individuals with comorbid ODD 
showed improvements at 1.8 mg/kg/day. Dell’Agnello et al. (2009) used a range of atomoxetine 
dosages (0.85 – 1.33 mg/kg/day) for ADHD patients with and without comorbid ODD. There 
was no specification made on whether the comorbid ODD patients required higher dosages. 
Lastly, one study observed children taking atomoxetine over nine months and results showed an 
overall prevention of relapse of ODD symptoms (Hazell et al., 2006). Thus atomoxetine must be 
titrated to reach an effective dosage which should be individualized to each patient. 
Clonidine in combination with either methlyphenidate or dexamphetamine showed to be 
effective in treating ODD symptoms (Hazell & Stuart, 2003). However, due to the small sample 
size more research is warranted. In regards to MAS XR, larger doses were needed to yield 
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desirable results in ODD management (Spencer et al., 2006). Lastly,the methylphenidate dosages 
produced reduced ODD symptom severity (Gadow et al., 2008).   
 
Safety of ADHD agents 
 ADHD pharmacologic agents are often well tolerated in children and adolescents because 
of the short half-lives of the medications. The most common adverse effects seen with 
atomoxetine included anorexia/decreased appetites, nausea, vomiting, fatigue, abdominal pain, 
sleep disorders, and decrease in body weight. One study had three participants discontinue due to 
adverse effects and observed less growth in height over the course of the trial (Dell’Agnello et 
al., 2009). MAS XR had similar adverse effects as atomoxetine including decreased appetite, 
weight loss, headache, insomnia, and abdominal pain (Spencer et al. 2006). Clonidine caused 
mostly dizziness and drowsiness which were expected. An interesting unexpected but postive 
effect of clonidine was a decrease in undesirable effects of concurrent psychotropic medications 
(Hazell & Stuart, 2003). Clonidine acts on central alpha receptors which decreases heart rate and 
blood pressure, hence the sedative effects. Lastly the immediate release methylphenidate, a 
commonly prescribed stimulant, casued an increase in heart rate and systolic blood pressure 
(Gadow et al., 2008). 
 
Previous Broad Diagnosis Criteria and DSM-V 
 Broad diagnosis criteria made ODD difficult to identify. Symptoms had to be present 
over a period of six months, however frequency was not specified in the DSM-IV criteria. The 
DSM-IV stated the word, “often” in the symptom list which left interpretation up to the 
healthcare provider (Keenan, 2012). With no methods to measure and gauge ODD symptoms, 
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diagnosis was difficult in differentiating between normal childhood misconduct and truly 
disruptive behavior. Contrastly, the DSM-V criteria has been made more specific in hopes of 
creating an easier diagnosis process. Symptoms have been placed into three groups including, 
angry/irritable mood, argumentative/defiant behavior, and vindictiveness. Exclusion critera for 
CD has been removed as well (American Psychiatric Association, 2013). Frequency of 
symptoms have been defined to address the issue of differentiating between normal childhood 
behavior and true signs of the disorder. Lastly, since ODD affects children and families across 
the lifespan, a severity rating has been added to gauge the extensiveness of the illness (American 
Psychiatric Association, 2013). Many of the issues with broad diagnosis criteria have been 
addressed in the DSM-V criteria. Providers now have an improved, proficient method to 
correctly diagnosing ODD.   
 
Information for school nurses 
 School nurses should be familiar with the presentation of ODD symptoms. Indications of 
ODD include but are not limited to, refusal to follow commands from adults, easily annoyed by 
others, hostility, verbally aggressive tendencies, spiteful behavior, stubborness, and inability to 
maintain healthy relationships with peers (Kledzik, Thorne, Prasad, Hayes, & Hines, 2012). A 
child with such widespread behavioral issues will most likely be known by various teachers and 
school staff. School nurses can be more effective when equipped with the knowledge to 
recognize ODD symptoms and intervene to assist with initiation of treatment. Early intervention 
is important because untreated ODD will steadily progress and cause greater problems later in 
life (Pardini & Fite, 2010). School nurses can play a huge role in treatment teams by helping to 
improve academic performance and assisting with the patient’s relationships with family and 
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friends (Barcalow, 2006). School nurses can be actively involved with facilitating and observing 
a child’s progression in treatment. 
 School nurses should be knowledgeable about all treatment options for students, 
including drug therapy, and what adverse effects to expect. Teachers and school nurses are often 
great sources of information when attempting to measure the efficacy of drug treatment in the 
shool setting. 
 
Implications 
 ODD affects 2 – 16 % of children and causes problems across the life span (4th ed., text-
rev.; DSM-IV-TR; American Psychiatric Association, 2000). Control of symptoms is important 
for quality of life for the child and family because ODD has been linked to later criminal charges 
and lifelong conduct problems (Pardini & Fite, 2010).  Early recognition, diagnosis, and 
effective and safe treatment are imperative to prevent future issues for affected children and 
adolescents. Pardini and Fite (2010) stated that ADHD symptoms worsen ODD and CD 
symptoms over time. The commonality of comorbid conditions with ODD, especially ADHD, 
further stresses the importance of knowledge of effective drug therapies. Although best results 
are seen with psychotherapy and drug therapy for ODD with comorbid disorders, more 
psychiatrisits and primary care physicians are solely using the drug therapy route (Harpaz-Rotem 
& Rosenheck, 2006). Healthcare providers should be educated on the most effective and safe 
drug therapy options in order to develop adequate treatment plans for patients. Extensive 
experiementation with several drugs on young children to find the right combination can become 
unethical and potentially dangerous. Lastly, nurses should know the presentation of ODD 
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(common signs and symptoms), how to effectively react to disruptive behavior, and what 
resources are available to the affected clients and families to facilitate child improvement. 
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Conclusions 
All of the articles synthesized suggest that ADHD agents are generally effective in 
controlling ODD symptoms and are relatively safe in school-age children. Adverse effects from 
drug therapy in children with ODD are present with all types of drug therapy and ODD symptom 
control has shown that the risks outweigh the benefits in this population. Drug therapy in 
combination with psychotherapy for both the parent and child has been shown to be a very 
effective form of treatment. School nurses can play a huge role in intervening and providing 
resources for treatment in order to prevent progression of oppositonal behavior. Healthcare 
providers collaborating with families and their chidren with ODD and having knowldege of the 
most effective and safe options can allow for an increase in quality of life for patients and 
families. 
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Limitations 
Six atomoxetine clinical trials were found which suggests effectiveness for the drug, 
however other ADHD agents are not as well researched in regards to ODD symptom control. Of 
the atomoxetine trials, two were not peer reviewed therefore while the articles were supportive of 
the effectiveness of atomoxetine in ODD symptom control, they were not approved by experts 
before publishing. The two non peer reviewed were not listed in the table of articles and the 
researcher found an adequate amount of peer reviewed atomoxetine studies to support 
conclusions. Only three additional clinical trails studying three different stimulants were found 
and critiqued. Although the three trials showed effectiveness in reducing ODD symptoms, 
further studies would have to be done for results to be generalizable to a larger population. 
Lastly, only one trial was found that studied the effectiveness of atomoxeitine over a matter of 
nine months. More research must be conducted to examine the sustainability of positive effects 
from ADHD agents in ODD symptom control.  
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Further research 
 Additonal research needs to be conducted to further examine the effectiveness of 
clonidine, MAS XR, and immediate release methylphenidate on controlling ODD symptoms. An 
additional study should be inititated investigating provider awareness of ODD symptoms and 
treatment to gauge education needs and increase knowledge among healthcare workers. 
 
 
 
 
  
22 
Appendix A: Table of Evidence 
Study 
(Author, 
Date, 
Journal) 
Duration  Drug and Mean 
Daily Dose 
Inclusion Criteria (age 
range) 
Efficacy and Safety Limitations 
Newcorn et 
al., (2005). 
Journal of 
the American 
Academy of 
Child & 
Adolescent 
Psychiatry, 
44(3), 240-
248. doi: 
10.1097/000
04583-
200503000-
00008 
8 weeks Atomoxetine 
-0.5 mg/kg/day 
(n=44) 
-1.2 mg/kg/day 
(n=83) 
-1.8 mg/kg/day 
(n=85) 
293 subjects 
-8 – 18  
-Normal intelligence (IQ 
≥80) 
-Diagnosed with ADHD 
with or without comorbid 
ODD according to DSM-
IV criteria 
-Attention 
Deficit/Hyperactivity 
Disorder Rating Scale-
IV-Parent version, 
investigator-administered 
and –scored scale ≥1.5 
SDs above age and 
gender normals 
-Subjects with ADHD 
and ODD showed most 
improvements at 1.8 
mg/kg/day 
-Subjects without ODD 
showed significant 
improvement at 1.2 
mg/kg/day 
-Individuals with 
ADHD and comorbid 
ODD may need higher 
dosages of atomoxetine 
to achieve desired 
effects 
 
-Efficacy of 
atomoxetine in 
controlling ODD 
symptoms was the 
secondary purpose of 
the study 
-Separating the 
subjects into smaller 
groups decreased the 
validity of the study 
findings. Further 
research is needed. 
Dell’Agnello 
et al., (2009). 
European 
Neuropsycho
pharmacolog
y, 19(11), 
822-834. doi: 
10.1016/j.eur
oneuro.2009.
07.008  
 
 
8 weeks Atomoxetine 
-Mean starting 
dose: 0.61 ± 
0.08 mg/kg/day 
(0.44-0.80) 
-Mean titrated 
dose: 1.10 ± 
0.13 mg/kg/day 
(0.85-1.33) 
137 subjects 
-6 – 15 
-Diagnosed with ADHD 
and ODD based on DSM-
IV criteria 
-Score ≥ 1.5 SD above 
age normal for ADHD 
subscale of SNAP-IV  
-SNAP-IV ODD subscale 
score of at least 15 
-CGI-S ≥4  
-IQ ≥ 70 
-ODD subscale 
changes were -2.7±4.1 
with the atomoxetine 
treated subjects 
(overall decrease in 
symptom severity) 
-At least 25%, 30%, or 
40% improvement in 
ADHD subscale scores 
-45.8% of atomoxetine 
group reported nausea, 
vomiting, and 
-Potential for bias 
because the 
researchers work for 
or are affiliated with 
the sponsor of the 
study: Eli Lilly Italy 
-Due to the duration 
there is no way to tell 
whether atomoxetine 
beneficial effects will 
persist over time 
23 
abdominal pain 
-43% of atomoxetine 
group reported 
anorexia/decreased 
appetite 
-3 atomoxetine treated 
subjects did not 
complete the study due 
to adverse effects 
-There was a small 
decrease in body 
weight and less height 
gain in atomoxetine 
treated subjects. 
However, nothing of 
significance. 
Bangs et al., 
(2008). 
Pediatrics, 
121(2), 
e314-20. 
8 weeks Atomoxetine 
-Mean final 
dose: 1.2 ± 0.28 
mg/kg per day 
-Mean 
maximum dose: 
1.52 ± 0.54 
mg/kg per day 
131 subjects 
-6 – 12 
-ADHD (any subtype) 
with comorbid ODD as 
primary diagnosis 
according to DSM-IV 
criteria 
-SNAP-IV ADHD 
subscale score ≥ 15 at 
both visits 1 and 2. 
-Clinical Global 
Impressions-Severity 
Scale score ≥ 4 at both 
visits 1 and 2. 
 
-Effective at 
controlling ODD 
symptoms at weeks 2 
and 5 but no significant 
difference at week 8.  
-More decreased 
appetite, nausea, 
fatigue. 
-Increased diastolic 
blood pressures and 
increased amount of 
weight loss. 
-No evidence 
atomoxetine would 
decrease ODD 
symptom would 
improve in absence of 
comorbid ADHD 
-Not possible to 
predict if reduced 
ODD symptom 
effects would last 
-Improvements seen 
in weeks 2 and 5 
could have been due 
to sedation effects 
-Allowing children 
with anxiety and 
dysthymic disorders 
24 
may have interfered 
with effectiveness of 
atomoxetine because 
these individuals 
struggled more. 
Hazell & 
Stuart. 
(2003). 
Journal of 
the American 
Academy of 
Child & 
Adolescent 
Psychiatry, 
42(8), 886-
894. doi: 
10.1097/01.
CHI.000004
6908.27264.
00 
6 weeks Clonidine 
-0.20 mg/day 
(n=25) 
-0.15 mg/day 
(n=4) 
-0.10 mg/day 
(n=6) 
67 subjects 
-6 – 14  
-White 
-Treated for minimum of 
3 months with either 
methylphenidate or 
dexamphetamine 
-Attended clinics 
supervised by authors 
-IQ ≥ 70 
-History of normal 
cardiac function 
-For subjects treated 
with clonidine, there 
was an increased 
reduction in Conduct 
and Hyperactivity 
Index Scores 
-Conners Parent Rating 
subscale scores showed 
a 25% improvement in 
the clonidine treated 
subjects  
-Side effects of 
concurrent 
psychotropic 
medication decreased 
in Clonidine treated 
patients 
-Symptom such as 
irritability, prone to 
crying, and anxiety 
were decreased with 
the clonidine treated 
group 
-Drowsiness and 
dizziness were the two 
main physical adverse 
effects  
 
-Small sample size 
-Validity and 
generalizability of the 
findings to a larger 
population may be 
limited due to the 
small sample size and 
the allowance of 
children with anxiety 
and below normal 
intellectual function 
to participate 
-A plethora of parents 
were able to correctly 
guess whether their 
child was getting 
clonidine or a placebo 
which may have led 
to bias 
-Duration too short to 
determine lasting 
benefits 
-No ECG data was 
collected  
25 
Spencer et 
al., (2006). 
Clinical 
Theraputics, 
28(3), 402-
418. 
4 weeks 
 
Mixed 
amphetamine 
salts extended 
release (MAS 
XR) (Adderall 
XR) 
-10 mg (n=60), 
--20 mg (n=58) 
-30 mg (n=69) 
-40 mg (n=61) 
308 subjects 
- 6 – 17  
-ODD with or without 
comorbid ADHD 
-Normal blood pressure 
and electrocardiographic 
reading 
-No additional illness that 
could interfere with the 
effectiveness and safety 
of MAS XR 
 
-Effective in 
decreasing from 
baseline ODD severity 
with MAS XR 30 mg/d 
and MAS XR 40 mg/d 
-MAS XR adverse 
effects: anorexia 
(25.3%), insomnia 
(19.5%), headache 
(18.5%), abdominal 
pain (10.7%) 
-1.1 to 3.5 pound 
decrease in body 
weight in MAS XR 
groups 
-Shorter duration 
-Dosages were not 
titrated to achieve 
optimal effects 
-Low baseline ODD 
subscale scores (less 
severe ODD 
symptoms) 
Gadow et al., 
(2008). 
Journal of 
Child 
Neurology, 
23(9), 981-
990. 
2 weeks Methylphenidat
e (Novartis 
Brand Ritalin-
IR) 
-0.1 mg/kg, 4.5 
mg 
-0.3 mg/kg, 9.3 
mg 
-0.5 mg/kg, 
14.3 mg 
31 subjects 
- 6 – 12  
-Met DSM-IV criteria for 
ODD, ADHD and either 
Tourette’s or chronic 
multiple tic disorder. 
-Previously part of a 
placebo-controlled, 
double-blind study of 
safety and efficacy of 
methylphenidate in 
school-age children with 
chronic tic disorder. 
-Mother and teacher 
ratings showed 
reduction in ODD 
symptom severity 
-Increase in heart rate 
and systolic blood 
pressures directly 
proportional to increase 
in methylphenidate 
dosage. 
-Short duration 
-The cause of ODD 
and ADHD in 
individuals with tic 
disorders is unknown, 
therefore response to 
medication may differ 
in children without a 
tic disorder  
-Rating scales 
completed by mothers 
are less effective at 
measuring severity of 
oppositional behavior 
at home. 
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